Abstract | BACKGROUND:
Zollinger-Ellison syndrome and idiopathic hypersecretion are gastrointestinal hypersecretory conditions requiring long-term maintenance. AIMS: The safety and efficacy data for short-term (6-month) treatment of Zollinger-Ellison syndrome and idiopathic hypersecretion with oral pantoprazole were previously published. This study extends the initial observations to 3 years. METHODS: The primary efficacy end point for this report was the control of gastric acid secretion in the last hour before the next dose of oral pantoprazole ( acid output of <10 mmol/h; <5 mmol/h in subjects with prior acid-reducing surgery). Dose titration was permitted to a maximum of 240 mg per 24 h. RESULTS: Twenty-four subjects completed the study. The acid output of 28 of 34 subjects was controlled at initial enrolment. The mean acid output rates were <10 mmol/h throughout the 36 months of treatment for 90-100% of the patients. The majority of the patients were controlled with b.d. doses of 40 or 80 mg pantoprazole at 36 months ( acid output was controlled in 24 of 24 subjects). Pantoprazole was generally well tolerated with minimal adverse events reported. CONCLUSIONS:
|
Authors | D C Metz, G M Comer, E Soffer, C E Forsmark, B Cryer, W Chey, J R Pisegna |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 23
Issue 3
Pg. 437-44
(Feb 01 2006)
ISSN: 0269-2813 [Print] England |
PMID | 16423003
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Anti-Ulcer Agents
- Benzimidazoles
- Sulfoxides
- Pantoprazole
- Omeprazole
|
Topics |
- 2-Pyridinylmethylsulfinylbenzimidazoles
- Administration, Oral
- Aged
- Anti-Ulcer Agents
(therapeutic use)
- Benzimidazoles
(therapeutic use)
- Dose-Response Relationship, Drug
- Female
- Gastric Acid
(metabolism)
- Humans
- Male
- Middle Aged
- Omeprazole
(analogs & derivatives, therapeutic use)
- Pantoprazole
- Prospective Studies
- Sulfoxides
(therapeutic use)
- Treatment Outcome
- Zollinger-Ellison Syndrome
(drug therapy)
|